Peptides DB
Research-centric peptide and protocol reference hub
Study 29 of 30Liraglutide literatureDiabetes, obesity & metabolism · ObservationalHigh-impact journal2026

Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.

Liraglutide is associated with a statistically significant risk of NAION, but this risk is lower than that of semaglutide. Clinicians should consider these findings when prescribing GLP-1RAs.

Read at Diabetes, obesity & metabolismAdd to compare

Where it sits

this study against the rest of the liraglutide corpus
6
Preclinical
16
Observational · this one
0
Open-label
3
Randomised
5
Reviews

Summary and findings

This study compared the risk of nonarteritic anterior ischemic optic neuropathy (NAION) among different glucagon-like peptide-1 receptor agonists (GLP-1RAs) including liraglutide. The analysis indicated that liraglutide had a hazard ratio (HR) of 1.251 for NAION compared to non-GLP-1RA treatments. The findings suggest a statistically significant but weaker risk signal for liraglutide compared to semaglutide.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
HR = 1.251, 95% CI: 1.080-1.450 for liraglutide compared to non-GLP-1RA treatments.2026

Abstract

The authors’ words, as Diabetes, obesity & metabolism supplied them

<h4>Aims</h4>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for Type 2 diabetes (T2DM) and obesity, but emerging evidence links them to nonarteritic anterior ischemic optic neuropathy (NAION). Whether this risk differs across agents and the underlying mechanisms remains unclear. We aimed to compare the risks of NAION associated with different GLP-1RAs and to explore the potential molecular mechanisms underlying this adverse reaction.<h4>Materials and methods</h4>A network meta-analysis was performed to quantitatively compare the differences in NAION risk. Real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) were used for validation. Network toxicology was further applied to identify central hub targets and signalling pathways. Molecular docking was conducted to evaluate the binding capacity of GLP-1RAs to central hub targets.<h4>Results</h4>The network meta-analysis revealed significant differences in NAION risk across GLP-1RAs. Compared with non-GLP-1RA treatments, semaglutide showed the highest risk (HR = 1.538, 95% CI: 1.305-1.816), followed by liraglutide (HR = 1.251, 95% CI: 1.080-1.450). FAERS pharmacovigilance analysis suggested a strong disproportionate signal for semaglutide (ROR = 94.534, 95% CI: 83.093-107.552) and a statistically significant but weaker signal for liraglutide (ROR = 4.519, 95% CI: 2.617-7.802). Network toxicology identified CASP3 as the central hub target, and pathway enrichment analysis revealed that the underlying mechanisms were primarily related to Alzheimer's disease, neurodegeneration pathways, and lipid and atherosclerosis pathways. Molecular docking suggested that semaglutide and liraglutide had high binding affinity to CASP3.<h4>Conclusions</h4>The combined strategy of network meta-analysis, pharmacovigilance, network toxicology and molecular docking provides insights into possible risk differences and potential mechanisms, and may guide future research on the safety profile of GLP-1RAs.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Liraglutide corpus

BUtilization of and gross spending on anti-obesity GLP-1 receptor agonists in state Medicaid programs, 2021 to 2026: a brand-level analysis of State Drug Utilization Databiorxiv-preprint · 2023 · Gross reimbursement increased from $24.7 million in 2021 to $4.44 billion in 2025.reviewCGenetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner.Life sciences · 2026 · Not reported in abstract.AnimalAGenetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial studybiorxiv-preprint · 2026 · n=134138 · Incretin receptor agonists increased serious fibro-capsular events with a Peto OR of 3·88, 95% CI 1·83–8·25; P = 4·1 × 10 −4.HumanBReal-world treatment-transition pathways and dosing patterns of insulin degludec/liraglutide in Chinese adults with type 2 diabetes.Metabolism open · 2026 · n=1499 · Mean HbA1c decreased by 1.66 percentage points; P < 0.001.HumanBEconomic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran.Journal of diabetes and metabolic disorders · 2026 · Incremental cost-effectiveness ratio of US$34,423.89/QALY for tirzepatide compared with semaglutide.reviewDInflammatory mechanisms of pancreatic β-cell dysfunction and therapeutic strategies in type 2 diabetes mellitus: a narrative review.Journal of diabetes and metabolic disorders · 2026 · Not reported in abstract.review